Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 28, 2023
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
Andreas Argyrides Maintained (BMRN) at Hold with Decreased Target to $74 on, Feb 28th, 2023
Andreas Argyrides of Wedbush, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Decreased Target from $83 to $74 on, Feb 28th, 2023.
Andreas has made no other calls on BMRN in the last 4 months.
There are 5 other peers that have a rating on BMRN. Out of the 5 peers that are also analyzing BMRN, 3 agree with Andreas's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023
- David Lebowitz of "Citigroup" Initiated at Hold and Held Target at $116 on, Tuesday, February 21st, 2023
- Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $107 on, Monday, January 30th, 2023
These are the ratings of the 2 analyists that currently disagree with Andreas
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023
- Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022
